Company Takeda announced the completion of the legal process of the merger with Shire in Russia and the reorganization of the Russian legal entity LLC “Shaer biotech Rus” in the form of joining to “Takeda pharmaceuticals”. The company also outlined plans to bring to the Russian market more than 10 new drugs for 5 years.
“As a result of the reorganization of OOO “Shaer biotech Rus” stopped the activity, and “Takeda pharmaceuticals” has become its legal successor for all liabilities. This kind of changes are administrative procedures on the way to the formation of the United company of Takeda and will not affect the production process, quality, efficiency and safety of the manufactured drugs”, – told in the press service of the Takeda.
On the merger of the Shire Takeda was announced in January 2019. Takeda identified a number of priority therapeutic areas: Oncology, gastroenterology, immunology, neurology, and genetic diseases. Targeted investments are also made in the development of vaccines and drugs in the blood plasma. Thanks to the merger, the company Takeda has expanded its global presence and has taken a leading position in Japan and the United States.